The Multiple Myeloma Therapy Market is expanding as the incidence of multiple myeloma increases and treatment options continue to advance. According to WiseGuyReports, the market was valued at approximately USD 37.4 billion in 2024 and is estimated at USD 39.8 billion in 2025, with the market projected to reach USD 75.0 billion by 2035 at a 6.5% CAGR from 2026 to 2035.
The therapy landscape is moving beyond conventional chemotherapy toward more targeted and personalized approaches. Major segments include chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. Targeted therapy represented about USD 15.0 billion in 2024 and is projected to reach USD 30.0 billion by 2035, supported by continued development of medicines designed to act more specifically on cancer cells.
Treatment demand also varies according to the stage of disease. The market covers initial treatment, relapsed treatment, and maintenance therapy, reflecting the long-term nature of multiple myeloma management. Oral, intravenous, and subcutaneous administration routes provide different treatment options, while adult and geriatric patients represent important demographic groups. Increasing investment in research and newer drug combinations is supporting innovation across these segments.
Regionally, North America holds the largest market position, with the regional market valued at approximately USD 17.2 billion in 2024 and projected to reach USD 32.5 billion by 2035. Europe maintains a significant presence, while Asia Pacific is developing as an important growth market as healthcare infrastructure, awareness, and access to advanced cancer therapies improve.
Future opportunities are closely connected with CAR-T cell therapy, monoclonal antibodies, immunotherapies, targeted medicines, and personalized treatment strategies. Recent industry developments include efforts to expand CAR-T manufacturing capacity and collaborations focused on next-generation BCMA-targeted therapies. As research continues to produce new treatment combinations and more individualized approaches, the multiple myeloma therapy market is expected to become increasingly technology-driven and innovation-focused.
